Somatropin vs tesamorelin: how these two prescription growth hormone drugs differ in mechanism, FDA-approved uses, dosing, side effects, and monthly cost.
Somatropin and tesamorelin both increase growth hormone (GH) signaling, but they do it in completely different ways. Somatropin is a synthetic form of human growth hormone that is injected directly, while tesamorelin is a growth hormone-releasing hormone (GHRH) analog that signals the pituitary gland to release more of the body's own GH. Both are prescription drugs in the United States, and both are FDA-approved only for narrow medical indications — not for general weight loss, anti-aging, or bodybuilding.
The Core Difference: Exogenous GH vs. a GHRH Analog
Somatropin is recombinant human growth hormone, a 191-amino-acid protein with the same sequence as the GH your pituitary produces. Injected subcutaneously, it enters circulation and binds GH receptors throughout the body directly. The pituitary's own output becomes largely irrelevant because the hormone is being supplied from outside.
Tesamorelin works one step upstream. It is a 44-amino-acid GHRH analog that binds GHRH receptors on pituitary cells, prompting them to release stored GH. That release then drives the liver and other tissues to produce insulin-like growth factor 1 (IGF-1), the same downstream pathway somatropin activates.
Two practical consequences follow. Tesamorelin depends on a functioning pituitary, so it behaves differently in someone with pituitary damage. Tesamorelin also preserves the body's feedback loops to some degree, while somatropin overrides them.
Somatropin replaces growth hormone directly; tesamorelin stimulates the pituitary to release the patient's own growth hormone.
FDA-Approved Uses and Legal Status
Somatropin is FDA-approved for pediatric and adult growth hormone deficiency, idiopathic short stature, short stature associated with Turner syndrome, Prader-Willi syndrome, chronic kidney disease, being born small for gestational age, and HIV-associated wasting. It is not FDA-approved as a general anti-aging or weight-loss drug.
Tesamorelin, sold as Egrifta SV, is FDA-approved for one thing: reducing excess visceral abdominal fat in adults with HIV and lipodystrophy. It is not FDA-approved for weight loss, bodybuilding, or anti-aging use, and it has not been approved for visceral fat reduction in people without HIV.
Both drugs are prescription-only in the United States. Buying either one from an overseas pharmacy or a "research chemical" site means you may receive counterfeit, underdosed, or contaminated product with no quality oversight.
Somatropin vs. Tesamorelin at a Glance
| Feature | Somatropin | Tesamorelin |
|---|---|---|
| Drug class | Recombinant human growth hormone | GHRH analog (GH secretagogue) |
| Mechanism | Supplies GH directly | Stimulates pituitary GH release |
| FDA-approved use | GHD, idiopathic short stature, Turner syndrome, Prader-Willi, CKD, HIV wasting | Excess visceral abdominal fat in HIV-associated lipodystrophy |
| Typical adult dose | Individualized, often 0.1–1 mg subcutaneously daily | 1.4 mg (Egrifta SV) subcutaneously once daily |
| IGF-1 effect | Direct, dose-dependent increase | Indirect increase via endogenous GH |
| Common side effects | Injection site reactions, edema, joint pain, carpal tunnel symptoms | Injection site reactions, joint and muscle pain, peripheral swelling |
| Pregnancy | Contraindicated | Contraindicated |
| Cost | Often thousands of dollars per month | Often thousands of dollars per month |
Dosing, IGF-1, and Body Composition Effects
Somatropin dosing is individualized. Clinicians typically start low, then titrate based on IGF-1 levels, symptoms, and side effects. Adults with growth hormone deficiency often use 0.1 to 0.4 mg per day, while higher doses are used in some pediatric and wasting indications.
Tesamorelin is dosed at a fixed 1.4 mg once daily with the Egrifta SV formulation. In clinical trials, tesamorelin reduced visceral adipose tissue by roughly 15 to 18 percent in adults with HIV-associated lipodystrophy over 26 to 52 weeks. The effect is specific to deep abdominal fat; subcutaneous fat and overall body weight change far less.
Growth hormone itself has been studied for body composition for decades. It can increase lean mass and reduce fat mass, but it also causes fluid retention and joint pain, and it does not build muscle the way resistance training and adequate protein do. Neither somatropin nor tesamorelin is a substitute for diet, exercise, or standard medical care for obesity.
Side Effects, Monitoring, and Who Should Avoid Them
Because both drugs raise GH and IGF-1, they share a similar risk profile, though the intensity differs.
- Injection site reactions: redness, pain, or nodules are common with both.
- Fluid retention: swelling of the hands and feet, joint pain, and carpal tunnel symptoms are more common with somatropin, especially at higher doses.
- Glucose effects: both can worsen insulin resistance, so people with diabetes need close monitoring.
- IGF-1 elevation: supraphysiologic IGF-1 levels are a theoretical long-term concern, which is why lab monitoring is part of standard care.
- Contraindications: active malignancy or pregnancy rules out both drugs. Tesamorelin labeling also calls for prostate-specific antigen (PSA) monitoring in men.
Anyone considering either medication should review their history, medications, and labs with a physician. Self-dosing with GH or GHRH peptides purchased online is not a monitored medical treatment.
How Tesamorelin Compares With Other GH-Related Peptides
Most people researching tesamorelin are also comparing it with other peptides that touch the GH axis.
Interest in aod 9604 vs tesamorelin usually comes down to fat loss. AOD-9604 is a fragment of the GH molecule studied for fat metabolism, and it is not FDA-approved for any human use. Tesamorelin is a full GHRH analog with a narrow FDA approval for visceral fat in HIV lipodystrophy.
Comparisons such as sermorelin vs tesamorelin and cjc-1295 ipamorelin vs tesamorelin involve peptides that are not FDA-approved for human use in the United States. Sermorelin is a shorter GHRH analog that has largely left the US market, CJC-1295 is a longer-acting GHRH analog used off-label, and ipamorelin is a ghrelin-receptor agonist often stacked with it.
A three-way framing like tesamorelin vs sermorelin vs cjc-1295 is really a question about half-life and potency rather than approved indications. None of these peptides has been shown in controlled trials to build muscle the way people hope, which makes tesamorelin vs cjc 1295 for muscle growth a comparison with a disappointing answer for both drugs.
The Bottom Line
Somatropin is exogenous growth hormone; tesamorelin is a signal that asks the pituitary to make more of its own. That single difference drives everything else — the FDA labeling, the dosing, the monitoring, and the side effect profile.
If the question is which one is stronger, somatropin delivers GH directly and produces larger, more predictable IGF-1 increases. If the question is which one has an approved indication for visceral fat, only tesamorelin does, and only in adults with HIV-associated lipodystrophy.
Neither drug is a shortcut for fat loss or muscle gain in healthy adults. Both carry real side effects, require lab monitoring, and should be used only under medical supervision.
Frequently Asked Questions
Is tesamorelin the same as growth hormone?
No. Tesamorelin is a growth hormone-releasing hormone analog that prompts the pituitary gland to release the body's own growth hormone, while somatropin is actual recombinant human growth hormone that is injected directly. The downstream effect on IGF-1 is similar, but the mechanism and the FDA-approved uses are different.
Which is better for belly fat, somatropin or tesamorelin?
Tesamorelin is the only one of the two that is FDA-approved specifically for reducing excess visceral abdominal fat, and that approval applies only to adults with HIV-associated lipodystrophy. Somatropin can reduce fat mass in studies, but it is not approved for fat loss and carries a higher risk of fluid retention and joint pain at the doses studied.
Can I buy somatropin or tesamorelin without a prescription?
No. Both are prescription-only in the United States, and the FDA has not approved any over-the-counter version of either drug. Products sold as research chemicals or shipped from overseas pharmacies are unregulated and may be counterfeit, mislabeled, or contaminated.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.